(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

USOS DE UM CONJUGADO ANTICORPO FÁRMACO

Em AnáliseInvention PatentPCT · US2023060062

Application data

Invention Patent USOS DE UM CONJUGADO ANTICORPO FÁRMACO de AGENSYS, INC. — IPC A61K 33/243
Invention Patent USOS DE UM CONJUGADO ANTICORPO FÁRMACO de AGENSYS, INC. — IPC A61K 33/243. Drawing published by the INPI in the Industrial Property Gazette.

Number

112024012993

Type

Invention Patent

Filing

01/04/2023

Publication

09/24/2024

PCT

US2023060062

Progress at the INPI

  1. Filing01/04/23
  2. Publication
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The application was filed at the INPI on 01/04/2023. It awaits formal examination and publication in the RPI gazette.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 08/26/2025. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

AGENSYS, INC.

US

SEAGEN INC.

US

See this company's full portfolio

Inventors

A. C. (pessoa física)

US

O. A. (pessoa física)

US

Technical data

Priority claims

US

63/296,831 · 01/05/2022

US

63/304,136 · 01/28/2022

Abstract

MÉTODO PARA TRATAR CÂNCER UROTELIAL INVASIVO MUSCULAR OU CÂNCER DE BEXIGA INVASIVO MUSCULAR COM CONJUGADOS ANTICORPO FÁRMACO (ADC) QUE LIGA ÀS PROTEÍNAS 191P4D12. A presente invenção refere-se a métodos para tratar cânceres uroteliais ou de bexiga com conjugados anticorpo droga (ADC) que ligam à proteína 191P4D12 (Nectina-4).

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Adição na publicação

#15.35

Referente à RPI 2803 de 24/09/2024, quanto ao item (54)

08/26/2025

RPI 2851

Notificação de entrada na fase nacional - PCT

#1.3

09/24/2024

RPI 2803

Alteração de dados cadastrais

#1.1

07/02/2024

RPI 2791

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.